At June 30, 2021 had approximately $100 million in unrestricted cash and cash equivalents, funds held in trust and short-term investments Development of FT-104, a novel psychedelic molecule with pending patents, continues to progress with GMP production achieved The Company remains on track to meet milestone of 20 sites open or under construction by December 2021 TORONTO, Aug. 16, 2021 (GLOBE…


Previous articlePsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs
Next articleDiamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin